Inventor · disambiguated record
Jeffrey David Kearns
Also filed as: KEARNS JEFFREY D · KEARNS JEFFREY DAVID
7 granted patents·10 pending applications·17 citations·filing 2012–2023
81Inventor score
Top patents by PatentIndex Score
17 records- 0189US9226964B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Granted Jan 5, 2016·9 cites·37 claims
- 0282US8691231B2Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodiesBUKHALID RAGHIDA·Filed 2012·Granted Apr 8, 2014·7 cites·17 claims
- 0372US9657108B2Dosage and administration of anti-EGFR therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted May 23, 2017·1 cites·6 claims
- 0465US2014234314A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0564US2017253662A1Dosage and administration of anti-egfr therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0663US9920131B2Dosage and administration of anti-EGFR therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Granted Mar 20, 2018·0 cites·18 claims
- 0762US2025197486A1Methods for treating neovascular age-related macular degenerationNOVARTIS AG·Filed 2023·Application pending·0 cites
- 0861US10072299B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Sep 11, 2018·0 cites·21 claims
- 0961US9902999B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 27, 2018·0 cites·21 claims
- 1061US9885087B2Antibodies against epidermal growth factor receptor (EGFR) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Feb 6, 2018·0 cites·21 claims
- 1161US2014170668A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1259US2017356049A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1357US2016251445A1Dosage and administration of anti-egfr therapeuticsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1455US2016083800A1Monoclonal and oligoclonal anti-egfr antibodies for use in the treatment of tumors expressing predominantly high affinity egfr ligands or tumors expressing predominantly low affinity egfr ligandsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1548US2023416351A1Vegf antagonist for use in methods for treating ocular diseasesNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1642US2017314079A1Antibodies against epidermal growth factor receptor (egfr) and uses thereofMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1730US2016311908A1Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jeffrey David Kearns files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →